1
|
Phongsamart W, Allen KE, Vandepitte WP, Techasaensiri C, Kosalaraksa P, Laoprasopwattana K, Khantee P, Udompornwattana S, Suwanpakdee D, Sudjaritruk T, Puthanakit T, Anugulruengkitt S, Southern J, Fletcher MA, Dunne EM, Thamaree R, Morales G, Chokephaibulkit K, Chotpitayasunondh T. Outcomes among Thai children with risk conditions hospitalized for pneumococcal disease (invasive or non-bacteraemic pneumonia): A multi-centre, observational study. IJID Reg 2023; 8:49-57. [PMID: 37415954 PMCID: PMC10319896 DOI: 10.1016/j.ijregi.2023.06.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/15/2023] [Revised: 05/26/2023] [Accepted: 06/01/2023] [Indexed: 07/08/2023]
Abstract
Objective To describe the risk condition status and clinical outcomes among Thai children hospitalized with pneumococcal disease. Methods In this retrospective analysis, children with invasive pneumococcal disease (IPD) or x-ray-confirmed non-bacteraemic pneumococcal pneumonia (NBPP) were identified from nine hospitals in Thailand between 2010 and 2019. Data on risk factors and outcomes were extracted from medical records. Results In total, 413 cases were identified: 319 IPD and 94 NBPP. Overall, 133 (32.2%) patients were admitted to intensive care units and 11/406 (2.7%) died. Twenty-seven percent of IPD cases had at-risk conditions and 15% had high-risk conditions. Most IPD cases (32.9%) occurred in children aged 2-4 years, and most NBPP cases (28.7%) occurred in infants aged 0-11 months. Of 51 Streptococcus pneumoniae isolates collected, 41 (80%) were pneumococcal 13-valent conjugate vaccine serotypes. Only 5.1% of children had received a pneumococcal vaccine. Conclusions Most children with IPD and NBPP did not have high-risk or at-risk conditions, while 42% had at-risk or high-risk conditions for pneumococcal disease. Very few children in the cohort had received any type of pneumococcal vaccine. Increasing the availability of pneumococcal conjugate vaccines should be considered to reduce the burden of pneumococcal disease among children in Thailand.
Collapse
Affiliation(s)
- Wanatpreeya Phongsamart
- Department of Paediatrics, Division of Infectious Diseases, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | | | | | - Chonnamet Techasaensiri
- Division of Infectious Diseases, Department of Paediatrics, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
| | - Pope Kosalaraksa
- Division of Infectious Disease, Department of Paediatrics, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
| | | | - Puttichart Khantee
- Department of Paediatrics, Faculty of Medicine, Prince of Songkla University, Songkla, Thailand
| | | | | | - Tavitiya Sudjaritruk
- Department of Paediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
| | - Thanyawee Puthanakit
- Division of Paediatric Infectious Diseases, Department of Paediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
| | - Suvaporn Anugulruengkitt
- Division of Paediatric Infectious Diseases, Department of Paediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
| | - Jo Southern
- Pfizer Biopharma Group, Collegeville, PA, USA
| | - Mark A. Fletcher
- Pfizer Biopharma Emerging Markets Medical Affairs, Vaccines, Paris, France
| | | | | | | | - Kulkanya Chokephaibulkit
- Department of Paediatrics, Division of Infectious Diseases, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | | |
Collapse
|